| Literature DB >> 26395086 |
Victoria Navarro-Compán1,2, Eugenio de Miguel3, Désirée van der Heijde4, Robert Landewé5,6, Raquel Almodóvar7, Carlos Montilla8, Emma Beltrán9, Pedro Zarco10.
Abstract
INTRODUCTION: Chronic back pain (CBP) is frequently the presenting symptom in patients with suspected axial spondyloarthritis (axSpA). Presence of sacroiliitis on magnetic-resonance-imaging (MRI) or HLA-B27 adds to diagnostic certainty. However, these costly tests cannot be applied in all patients with CBP. This study aims to investigate which SpA features increase the likelihood of a positive HLA-B27 or positive MRI of the sacroiliac-joints (MRI-SI) in patients with suspected axSpA.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26395086 PMCID: PMC4580040 DOI: 10.1186/s13075-015-0779-y
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Baseline characteristics for all patients with axial symptoms included in Esperanza (left column) and for the subgroup of patients who underwent MRI-SI (right column)
| Characteristic | Patients with axial symptoms referred to Esperanza (n = 665) | Patients with axial symptoms and SIJ MRI available (n = 326) |
|---|---|---|
| Age, years | 33.2 ± 7.1 | 32.8 ± 7.0 |
| Male | 363 (54.6) | 175 (53.7) |
| Symptoms duration, months | 11.9 ± 6.6 | 12.6 ± 6.4 |
| Morning stiffness | 393 (59.1) | 195 (59.8) |
| Improve with exercise, not with rest | 208 (31.3) | 97 (29.8) |
| Alternating buttock pain | 197 (29.6) | 98 (30.1) |
| Insidious onset | 430 (64.7) | 256 (78.5) |
| Awakening at second half of night | 315 (47.4) | 169 (51.8) |
| Response to NSAIDs | 407 (61.2) | 200 (61.3) |
| Enthesitis | 107 (16.1) | 45 (13.8) |
| Psoriasis | 82 (12.3) | 35 (10.7) |
| Dactylitis | 26 (3.9) | 14 (4.3) |
| IBD | 26 (3.9) | 10 (3.1) |
| Uveitis | 34 (5.1) | 16 (4.9) |
| Arthritis | 95 (14.3) | 37 (11.3) |
| Family history | 170 (25.6) | 89 (27.3) |
| HLA-B27 | 270 (40.6) | 144 (44.2) |
| Elevated CRP, mg/L | 177 (26.6) | 89 (27.3) |
| BASDAI | 4.0 ± 2.3 | 3.9 ± 2.3 |
| BASFI | 2.5 ± 2.4 | 2.3 ± 2.4 |
| ASAS criteria for axial SpA | 291 (43.8) | 167 (51.2) |
| Imaging arm | 194 (29.2) | 132 (40.5) |
| MRI-SI positive | 85 (12.8) | 85 (26.1) |
| mNY-positivea | 109 (16.4) | 47 (14.4) |
| Clinical arm only | 97 (14.6) | 35 (10.7) |
Results are presented as mean ± SD or number (%). aPatients who were both magnetic resonance imaging of sacroiliac joints (MRI-SI)-positive and modified New York criteria for ankylosing spondylitis (mNY)-positive) are included. NSAIDs nonsteroidal anti-inflammatory drugs, IBD inflammatory bowel disease, HLA-B27 human leucocyte antigen B27, CRP C-reactive protein, BASDAI Bath ankylosing spondylitis disease activity index, BASFI Bath ankylosing spondylitis functional index, ASAS Assessment of SpondyloArthritis International Society, SpA spondyloarthritis
Values for diagnostic utility measures for each of the inflammatory back pain characteristics in relation to the presence of sacroiliitis on MRI, and positive HLA-B27 testing
| Sacroiliitis on MRI | HLA-B27 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sen | Spe | LR+ | LR− | PPV | NPV | Sen | Spe | LR+ | LR− | PPV | NPV | |
| Morning stiffness for >30 minutes | 68.5 | 45.9 | 1.3 | 0.7 | 45.6 | 68.7 | 63.3 | 43.6 | 1.1 | 0.8 | 44.2 | 62.8 |
| Improvement with exercise, not with rest | 31.5 | 71.4 | 1.1 | 0.1 | 42.3 | 61.1 | 33.7 | 70.2 | 1.1 | 0.9 | 44.4 | 60.0 |
| Alternating buttock pain | 47.7 | 81.6 | 2.6 | 0.6 | 63.3 | 70.2 | 31.9 | 71.3 | 1.1 | 0.9 | 43.9 | 59.7 |
| Insidious onset | 87.7 | 27.6 | 1.2 | 0.4 | 44.5 | 77.1 | 68.1 | 37.1 | 1.1 | 0.9 | 43.3 | 62.3 |
| Awakening in second half of the night | 64.6 | 56.6 | 1.5 | 0.6 | 49.7 | 70.7 | 55.2 | 57.4 | 1.3 | 0.8 | 47.8 | 64.5 |
| Response to NSAIDs | 69.2 | 43.9 | 1.2 | 0.7 | 45.0 | 68.3 | 67.4 | 43.3 | 1.2 | 0.8 | 45.6 | 65.4 |
MRI magnetic resonance imaging, HLA-B27 human leucocyte antigen B27, Sen sensitivity, Spe specificity, LR+ positive likelihood ratio, LR− negative likelihood ratio, PPV positive predictive value, NPV negative predictive value, NSAIDs nonsteroidal anti-inflammatory drugs
Values for diagnostic utility measures for each of the inflammatory back pain definitions and other features of SpA in relation to the presence of sacroiliitis on MRI and positive HLA-B27 testing
| Sacroiliitis on MRI | HLA-B27 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sen | Spe | LR+ | LR− | PPV | NPV | Sen | Spe | LR+ | LR− | PPV | NPV | |
| IBP definition | ||||||||||||
| Calin criteria | 51.5 | 70.9 | 1.8 | 0.7 | 54.0 | 68.8 | 36.3 | 74.2 | 1.4 | 0.9 | 49.7 | 62.3 |
| Berlin criteria | 72.3 | 50.5 | 1.5 | 0.6 | 49.2 | 73.3 | 64.1 | 49.3 | 1.3 | 0.7 | 47.1 | 66.1 |
| ASAS criteria | 47.7 | 77.0 | 2.1 | 0.7 | 57.9 | 68.9 | 31.5 | 80.7 | 1.6 | 0.9 | 53.5 | 62.3 |
| IBP definition plus other IBP characteristics | ||||||||||||
| Calin + alt. buttock | 30.8 | 94.9 | 6.0 | 0.7 | 80.0 | 67.4 | 17.4 | 86.4 | 1.3 | 1.0 | 51.0 | 56.3 |
| Calin + NSAIDs | 36.2 | 80.1 | 1.8 | 0.8 | 54.7 | 65.4 | 28.5 | 75.7 | 1.2 | 0.9 | 48.8 | 56.5 |
| Calin + night | 28.0 | 94.9 | 5.5 | 0.8 | 77.8 | 67.4 | 16.2 | 87.9 | 1.3 | 1.0 | 52.3 | 56.3 |
| Calin + alt. buttock + night | 26.9 | 94.9 | 5.3 | 0.8 | 77.8 | 66.2 | 16.0 | 88.1 | 1.3 | 1.0 | 52.3 | 56.3 |
| Calin + alt. buttock + NSAIDs | 20.0 | 96.9 | 6.5 | 0.8 | 81.3 | 64.6 | 10.4 | 91.0 | 1.2 | 1.0 | 48.4 | 55.5 |
| Calin + Night + NSAIDs | 29.2 | 87.2 | 2.3 | 0.8 | 60.3 | 65.0 | 21.5 | 88.3 | 1.8 | 0.9 | 56.3 | 61.5 |
| Berlin + Insidious | 64.6 | 62.2 | 1.7 | 0.6 | 53.1 | 72.6 | 50.7 | 53.1 | 1.1 | 0.9 | 46.8 | 57.0 |
| Berlin + NSAIDs | 53.8 | 68.4 | 1.7 | 0.7 | 53.0 | 69.1 | 48.9 | 66.1 | 1.4 | 0.8 | 50.4 | 64.7 |
| Berlin + insidious + NSAIDs | 47.7 | 76.0 | 2.0 | 0.7 | 56.9 | 68.7 | 34.0 | 67.2 | 1.0 | 1.0 | 45.8 | 55.6 |
| ASAS + alt. Buttock | 30.8 | 94.4 | 5.5 | 0.7 | 78.4 | 94.4 | 18.1 | 86.4 | 1.3 | 0.9 | 52.0 | 56.5 |
| ASAS + NSAIDs | 36.9 | 86.2 | 2.7 | 0.7 | 64.0 | 67.3 | 24.4 | 82.0 | 1.4 | 0.9 | 56.4 | 61.9 |
| ASAS + stiffness | 39.2 | 81.1 | 2.1 | 0.7 | 58.0 | 66.8 | 31.3 | 76.3 | 1.3 | 0.9 | 51.7 | 57.7 |
| ASAS + alt. Buttock + NSAIDs | 21.5 | 96.4 | 6.0 | 0.8 | 80.0 | 64.9 | 10.7 | 94.3 | 1.9 | 0.9 | 56.9 | 94.3 |
| ASAS + stiffness + NSAIDs | 28.5 | 88.8 | 2.5 | 0.8 | 62.7 | 65.2 | 19.4 | 83.1 | 1.1 | 1.0 | 48.3 | 55.9 |
| ASAS + stiffness + alt. buttock | 26.9 | 94.9 | 5.3 | 0.8 | 77.8 | 66.2 | 16.0 | 88.1 | 1.3 | 1.0 | 52.3 | 56.3 |
| Other SpA features | ||||||||||||
| Enthesitis | 11.5 | 84.7 | 0.8 | 1.0 | 33.3 | 59.1 | 17.8 | 85.1 | 1.2 | 0.9 | 85.1 | 45.7 |
| Peripheral arthritis | 13.8 | 90.3 | 1.4 | 0.9 | 48.6 | 61.2 | 16.7 | 87.7 | 1.4 | 0.9 | 87.7 | 48.9 |
| Dactylitis | 23.1 | 94.4 | 4.1 | 0.8 | 21.4 | 59.3 | 4.8 | 96.9 | 1.6 | 09 | 96.9 | 52.0 |
| Uveitis | 6.2 | 95.9 | 1.5 | 0.9 | 50.0 | 60.6 | 8.1 | 96.9 | 2.6 | 0.9 | 96.9 | 64.7 |
| Psoriasis | 10.0 | 88.8 | 0.9 | 1.0 | 37.1 | 59.8 | 7.0 | 83.8 | 0.4 | 1.1 | 83.8 | 23.5 |
| Inflammatory bowel disease | 23.1 | 96.4 | 6.4 | 0.8 | 30.0 | 59.8 | 1.5 | 94.5 | 0.3 | 1.0 | 94.5 | 16.0 |
| Family history of SpA | 27.7 | 73.0 | 1.0 | 0.9 | 40.4 | 60.3 | 33.7 | 80.2 | 1.7 | 0.8 | 80.2 | 54.5 |
| Elevated CRP | 40.8 | 77.5 | 1.8 | 0.8 | 55.1 | 66.0 | 38.5 | 77.1 | 1.7 | 0.8 | 77.1 | 54.6 |
| HLA-B27 | 59.7 | 65.1 | 1.7 | 0.6 | 53.5 | 70.6 | – | – | – | – | – | – |
MRI magnetic resonance imaging, HLA-B27 human leucocyte antigen B27, Sen sensitivity, Spe specificity, LR+ positive likelihood ratio, LR− negative likelihood ratio, PPV positive predictive value, NPV negative predictive value, ASAS Assessment of SpondyloArthritis International Society, Alt. alternating, NSAIDs nonsteroidal anti-inflammatory drugs, SpA spondyloarthritis, CRP C-reactive protein